Name: XY028-133
Brand: BOC Sciences
Rating: 5 (1 reviews)

Size

Price

Stock

Quantity

$--

In stock

Purity

≥98%

Solubility

DMSO: 50 mg/mL (49.89 mM; Need ultrasonic)

Appearance

Solid

Storage

Store at -20°C, sealed storage, away from moisture and light

IUPACName

(2S,4R)-1-[(2S)-2-[[7-[4-[6-[(6-acetyl-8-cyclopentyl-5-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl)amino]pyridin-3-yl]piperazin-1-yl]-7-oxoheptanoyl]amino]-3,3-dimethylbutanoyl]-4-hydroxy-N-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide

Synonyms

N-[7-(4-{6-[(6-Acetyl-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino]-3-pyridinyl}-1-piperazinyl)-7-oxoheptanoyl]-3-methyl-L-valyl-(4R)-4-hydroxy-N-[4-(4-methyl-1,3-thiazol-5-yl)benzyl]-L-prolinamide; (2S,4R)-1-((S)-2-(7-(4-(6-((6-acetyl-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)pyridin-3-yl)piperazin-1-yl)-7-oxoheptanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide

Density

1.3±0.1 g/cm3

InChI Key

MWVNDEBEHBRZEC-WWTLGBROSA-N

InChI

InChI=1S/C53H67N11O7S/c1-32-40-29-56-52(60-48(40)64(37-12-10-11-13-37)50(70)45(32)34(3)65)58-42-21-20-38(28-54-42)61-22-24-62(25-23-61)44(68)15-9-7-8-14-43(67)59-47(53(4,5)6)51(71)63-30-39(66)26-41(63)49(69)55-27-35-16-18-36(19-17-35)46-33(2)57-31-72-46/h16-21,28-29,31,37,39,41,47,66H,7-15,22-27,30H2,1-6H3,(H,55,69)(H,59,67)(H,54,56,58,60)/t39-,41+,47-/m1/s1

SMILES

CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCN(CC4)C(=O)CCCCCC(=O)NC(C(=O)N5CC(CC5C(=O)NCC6=CC=C(C=C6)C7=C(N=CS7)C)O)C(C)(C)C)C8CCCC8)C(=O)C

Mechanism

Target: XY028-133 targets cyclin-dependent kinases CDK4 and CDK6 for degradation.

Binding site: Its CDK-recognition ligand binds the ATP-competitive catalytic sites of CDK4/6.

Mechanism of action: XY028-133 is a VHL-based CDK4/6 PROTAC composed of a CDK ligand connected to a von Hippel-Lindau E3 ligase ligand. By simultaneously engaging CDK4 or CDK6 and VHL, XY028-133 is designed to promote ternary-complex formation, ubiquitin transfer, and proteasome-dependent degradation of the cell-cycle kinases. This mechanism enables experimental evaluation of CDK4/6 protein depletion rather than reversible enzymatic inhibition alone. XY028-133 is suitable for studies of RB pathway control, kinase paralog redundancy, degradation selectivity, and cellular consequences of sustained CDK4/6 removal.

Applications

• PROTAC-Mediated Targeted Degradation: XY028-133 is instrumental in facilitating the targeted degradation of disease-relevant proteins, offering a novel approach to studying protein function and regulation. Researchers can leverage this product to dissect complex biological pathways and investigate the impact of protein loss on cellular processes.

• Investigating Protein-Protein Interactions: Utilizing XY028-133 in research allows for the exploration of protein-protein interactions by selectively degrading one protein component. This approach aids in understanding the dynamic roles of proteins within various signaling cascades and their contribution to cellular homeostasis.

• Protein Degradation Mechanism Studies: XY028-133 serves as a valuable tool for elucidating the mechanisms underpinning PROTAC-mediated protein degradation. By examining the degradation kinetics and specificity, researchers can gain insights into the efficiency and selectivity of this innovative therapeutic strategy.

• Advancing Drug Discovery: The application of XY028-133 in drug discovery research enables the identification of novel therapeutic targets through the precise degradation of proteins implicated in disease. This product supports the development of next-generation therapeutics by validating target proteins and understanding their biological significance.

Stock concentration: *

Desired final volume: *

Desired concentration: *

* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C₁V₁ = C₂V₂